Henlius Entered into a License and Supply Agreement with Getz Pharma to Commercialise Handayua (biosimilar, adalimumab)
Shots:
- Getz pharma gets the license to commercialize adalimumab biosimilar in the Islamic Republic of Pakistan, the Philippines, Vietnam, Cambodia, Myanmar, Nigeria, Kenya, Sri Lanka, Ukraine, Kazakhstan and Uzbekistan, and other countries
- The collaboration will enhance Henlius’ global commercialization and accelerates brand awareness in emerging markets. Henlius will be responsible to provide more high-quality treatment options to patients in South Asia, Southeast Asia, Africa, and the CIS
- Henlius’ HLX03 is the first self-developed mAb for autoimmune treatment & has been approved in China for the treatment of RA, AS, Ps & UV. Adalimumab has been approved for ~10 indications globally
Ref: Henlius | Image: Henlius
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
